## Milena S Nicoloso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9207556/publications.pdf

Version: 2024-02-01

54 papers 8,024 citations

38 h-index 52 g-index

55 all docs 55 docs citations

55 times ranked 12838 citing authors

#	Article	IF	CITATIONS
1	A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13556-13561.	7.1	990
2	E2F1-Regulated MicroRNAs Impair TGF $\hat{I}^2$ -Dependent Cell-Cycle Arrest and Apoptosis in Gastric Cancer. Cancer Cell, 2008, 13, 272-286.	16.8	818
3	MicroRNAs — the micro steering wheel of tumour metastases. Nature Reviews Cancer, 2009, 9, 293-302.	28.4	740
4	<i>CCAT2</i> , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461.	5.5	526
5	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. Clinical Cancer Research, 2009, 15, 5060-5072.	7.0	386
6	Single-Nucleotide Polymorphisms Inside MicroRNA Target Sites Influence Tumor Susceptibility. Cancer Research, 2010, 70, 2789-2798.	0.9	365
7	MicroRNA Fingerprints Identify miR-150 as a Plasma Prognostic Marker in Patients with Sepsis. PLoS ONE, 2009, 4, e7405.	2.5	273
8	p27Kip1-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell, 2005, 7, 51-63.	16.8	259
9	Association of a MicroRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-Cell Chronic Lymphocytic Leukemia. JAMA - Journal of the American Medical Association, 2011, 305, 59.	7.4	256
10	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-α in human breast cancer cells. Cell Death and Differentiation, 2010, 17, 246-254.	11.2	231
11	MiR-15a and MiR-16 Control Bmi-1 Expression in Ovarian Cancer. Cancer Research, 2009, 69, 9090-9095.	0.9	229
12	SnapShot: MicroRNAs in Cancer. Cell, 2009, 137, 586-586.e1.	28.9	223
13	MicroRNAs and cancer—new paradigms in molecular oncology. Current Opinion in Cell Biology, 2009, 21, 470-479.	5.4	219
14	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood, 2010, 116, 945-952.	1.4	200
15	Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. Gastroenterology, 2012, 142, 886-896.e9.	1.3	174
16	p63–microRNA feedback in keratinocyte senescence. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1133-1138.	7.1	161
17	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discovery, 2013, 3, 1302-1315.	9.4	140
18	<i>miRâ€29b</i> and <i>miRâ€125a</i> regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes and Cancer, 2010, 49, 981-990.	2.8	125

#	Article	IF	CITATIONS
19	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	7.0	122
20	Stathmin Activity Influences Sarcoma Cell Shape, Motility, and Metastatic Potential. Molecular Biology of the Cell, 2008, 19, 2003-2013.	2.1	121
21	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut, 2016, 65, 977-989.	12.1	111
22	Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. Scientific Reports, 2013, 3, 2687.	3.3	104
23	Association of Wwox with ErbB4 in Breast Cancer. Cancer Research, 2007, 67, 9330-9336.	0.9	99
24	HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts. Cell Death and Differentiation, 2013, 20, 1675-1687.	11.2	99
25	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biology, 2017, 18, 98.	8.8	97
26	MicroRNA Involvement in Brain Tumors: From Bench to Bedside. Brain Pathology, 2008, 18, 122-129.	4.1	90
27	p27 <sup>kip1</sup> Controls Cell Morphology and Motility by Regulating Microtubule-Dependent Lipid Raft Recycling. Molecular and Cellular Biology, 2010, 30, 2229-2240.	2.3	68
28	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis, 2010, 31, 208-215.	2.8	68
29	Fez1/Lzts1 Absence Impairs Cdk1/Cdc25C Interaction during Mitosis and Predisposes Mice to Cancer Development. Cancer Cell, 2007, 11, 275-289.	16.8	67
30	p27kip1 Functional Regulation in Human Cancer: A Potential Target for Therapeutic Designs. Current Medicinal Chemistry, 2005, 12, 1589-1605.	2.4	66
31	Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene, 2016, 35, 4914-4926.	5.9	63
32	Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer. PLoS ONE, 2012, 7, e41170.	2.5	59
33	MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. British Journal of Haematology, 2007, 139, 709-716.	2.5	56
34	MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocrine-Related Cancer, 2010, 17, F51-F75.	3.1	53
35	Alterations of the Tumor Suppressor Gene ARLTS1 in Ovarian Cancer. Cancer Research, 2006, 66, 10287-10291.	0.9	47
36	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. Clinical Cancer Research, 2010, 16, 620-628.	7.0	44

#	Article	IF	Citations
37	Coordinated Targeting of the EGFR Signaling Axis by MicroRNA-27a*. Oncotarget, 2013, 4, 1388-1398.	1.8	44
38	Prostaglandin E2 Inhibits Proliferation and Migration of HTR-8/SVneo Cells, a Human Trophoblast-derived Cell Line. Placenta, 2006, 27, 592-601.	1.5	43
39	Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 2512.	4.1	30
40	HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene, 2005, 24, 6809-6819.	5.9	29
41	Linking Inflammation to Cell Cycle Progression. Current Pharmaceutical Design, 2004, 10, 1653-1666.	1.9	22
42	TIMP-1 Is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells. Cells, 2020, 9, 6.	4.1	20
43	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 3805.	4.1	17
44	BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress. Cell Death and Disease, 2016, 7, e2374-e2374.	6.3	16
45	Sleeping beauty genetic screen identifies miR-23b::BTBD7 gene interaction as crucial for colorectal cancer metastasis. EBioMedicine, 2019, 46, 79-93.	6.1	13
46	<scp><i>CDKN1B</i></scp> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. Journal of Pathology, 2021, 253, 234-245.	4.5	12
47	Following MicroRNAs Through the Cancer Metastatic Cascade. International Review of Cell and Molecular Biology, 2017, 333, 173-228.	3.2	5
48	MicroRNAs as new biomarkers in oncology. Expert Opinion on Medical Diagnostics, 2008, 2, 115-127.	1.6	4
49	In silico prediction of target SNPs affecting miR-mRNA interaction. , 2008, , .		2
50	MicroRNAs: The Jack of All Trades. Clinical Leukemia, 2009, 3, 20-32.	0.2	2
51	MicroRNAs: New Players in AML Pathogenesis. Cancer Treatment and Research, 2009, 145, 169-181.	0.5	2
52	Abstract 1483: Biological and clinical significance of miR-224 in colorectal cancer., 2014,,.		1
53	Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA) Journal of Clinical Oncology, 2019, 37, 5564-5564.	1.6	1
54	Small silencing non-coding RNAs: cancer connections and significance., 0,, 481-496.		O